Interleukin-2-dependent Control of Disease Development in Spontaneously Diabetic BB Rats

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1990 Feb 1

PMID 2307481

Citations 4

Authors

J Zielasek

V Burkart

P Naylor

A Goldstein

U Kiesel

H Kolb

Affiliations

Soon will be listed here.

Abstract

Long-term treatment with recombinant interleukin-2 (IL-2) of diabetes-prone BB rats had contrasting effects in two different BB rat sublines. Diabetes development was enhanced in the subline with a low intrinsic diabetes risk and suppressed in the subline with a high diabetes risk. IL-2 treatment started between 35 and 42 days of age and lasted for 3 months. In subline 1, diabetes incidence increased from 23% to 53% (P less than 0.01), in subline 2 it decreased from 73% to 32% (P less than 0.01). The two sublines differed in serum levels of factors controlling IL-2 synthesis and activity. Mean IL-2 inhibitory activity was higher in subline 2 (between 140% and 290% of levels in subline 1, P less than 0.01). Conversely, mean concentrations of thymosin alpha 1 and beta 4 were higher in subline 1 (between 140% and 200% of levels in subline 2, P less than 0.01). Thus the two sublines differ in their response to exogenous IL-2 and also in serum levels of mediators affecting availability of IL-2. We conclude that an internal network of hormonal factors, including IL-2, contributes to the control of diabetes development in the BB rat.

Citing Articles

Low-dose interleukin-2 promotes STAT-5 phosphorylation, T survival and CTLA-4-dependent function in autoimmune liver diseases.

Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G Clin Exp Immunol. 2017; 188(3):394-411.

PMID: 28176332 PMC: 5422719. DOI: 10.1111/cei.12940.

Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Setoguchi R, Hori S, Takahashi T, Sakaguchi S J Exp Med. 2005; 201(5):723-35.

PMID: 15753206 PMC: 2212841. DOI: 10.1084/jem.20041982.

Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes.

Moritani M, Yoshimoto K, Ii S, Kondo M, Iwahana H, Yamaoka T J Clin Invest. 1996; 98(8):1851-9.

PMID: 8878437 PMC: 507625. DOI: 10.1172/JCI118986.

Imbalance of the interleukin 2 system in children with IDDM.

Tomoda T, Kurashige T, Taniguchi T Diabetologia. 1994; 37(5):476-82.

PMID: 8056185 DOI: 10.1007/s001250050135.

References

Burstein D, HANDLER E, Schindler J, SEALS J, Mordes J, Rossini A . Effect of interleukin-2 on diabetes in the BB/Wor rat. Diabetes Res. 1987; 5(4):163-7. View

Winter W, Robbins V, Elder M, Barrett D, Martin N, Maclaren N . Thymosin and the spontaneously diabetic BB rat. Autoimmunity. 1988; 1(2):115-23. DOI: 10.3109/08916938809001924. View

Kucharz E, Goodwin J . Serum inhibitors of interleukin-2. Life Sci. 1988; 42(16):1485-91. DOI: 10.1016/0024-3205(88)90004-5. View

Naylor P, Goldstein A . Thymosin modulates immune and endocrine events. Prog Clin Biol Res. 1988; 256:489-502. View

Lelchuk R, Playfair J . Serum IL-2 inhibitor in mice. I. Increase during infection. Immunology. 1985; 56(1):113-8. PMC: 1453670. View

Male D, Lelchuk R, Curry S, Pryce G, Playfair J . Serum IL-2 inhibitor in mice. II. Molecular characteristics. Immunology. 1985; 56(1):119-25. PMC: 1453661. View

Reem G, Yeh N, Urdal D, Kilian P, Farrar J . Induction and upregulation by interleukin 2 of high-affinity interleukin 2 receptors on thymocytes and T cells. Proc Natl Acad Sci U S A. 1985; 82(24):8663-6. PMC: 391496. DOI: 10.1073/pnas.82.24.8663. View

Pontesilli O, Chase H, Carotenuto P, Herberger M, Hayward A . T-lymphocyte subpopulations in insulin-dependent (type I) diabetes mellitus. Clin Exp Immunol. 1986; 63(1):68-72. PMC: 1577341. View

Kolb H, Zielasek J, Treichel U, FREYTAG G, Wrann M, Kiesel U . Recombinant interleukin 2 enhances spontaneous insulin-dependent diabetes in BB rats. Eur J Immunol. 1986; 16(2):209-12. DOI: 10.1002/eji.1830160218. View

10.

Maki T, Satomi S, Gotoh M, Monaco A . Contra-IL 2; a suppressor lymphokine that inhibits IL 2 activity. J Immunol. 1986; 136(9):3298-303. View

11.

Duclos H, Maillot M, Galanaud P . Interleukin induction of non-specific suppressor cells. Ann Inst Pasteur Immunol (1985). 1986; 137C(1):3-10. DOI: 10.1016/s0771-050x(86)80001-8. View

12.

Dyrberg T, Kastern W . Genetic heterogeneity in the major histocompatibility complex of various BB rat sublines. Diabetologia. 1986; 29(5):307-12. DOI: 10.1007/BF00452068. View

13.

Frasca D, Adorini L, Mancini C, Doria G . Reconstitution of T cell functions in aging mice by thymosin alpha 1. Immunopharmacology. 1986; 11(3):155-63. DOI: 10.1016/0162-3109(86)90017-2. View

14.

Sztein M, Serrate S, Goldstein A . Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc Natl Acad Sci U S A. 1986; 83(16):6107-11. PMC: 386448. DOI: 10.1073/pnas.83.16.6107. View

15.

Gearing A, Wadhwa M, Perris A . In vivo administration of interleukin 2 stimulates mitosis in thymus and bone marrow. Eur J Immunol. 1986; 16(9):1171-4. DOI: 10.1002/eji.1830160923. View

16.

Kaye W, Adri M, Soeldner J, Rabinowe S, Kaldany A, Kahn C . Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N Engl J Med. 1986; 315(15):920-4. DOI: 10.1056/NEJM198610093151502. View

17.

Naylor P, Friedman-Kien A, Hersh E, Erdos M, Goldstein A . Thymosin alpha 1 and thymosin beta 4 in serum: comparison of normal, cord, homosexual and AIDS serum. Int J Immunopharmacol. 1986; 8(7):667-76. DOI: 10.1016/0192-0561(86)90001-9. View

18.

Fujiwara H, Toossi Z, Ohnishi K, Edmonds K, Ellner J . Spontaneous production of a suppressor factor by a human macrophage-like cell line U937. II. Suppression of antigen- and mitogen-induced blastogenesis, IL 2 production and IL 2 receptor expression in T lymphocytes. J Immunol. 1987; 138(1):197-203. View

19.

Djeu J, Kasahara T, Balow J, Tsokos G . Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders. Clin Exp Immunol. 1986; 65(2):279-85. PMC: 1542294. View

20.

Gillis S, Ferm M, Ou W, Smith K . T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978; 120(6):2027-32. View